| 供应商 | 上海联迈生物工程有限公司 |
| 数量 | 大量 |
| 靶点 | 详见说明书 |
| 级别 | 1 |
| 目录编号 | LM-13447R-FITC |
| 克隆性 | 多克隆 |
| 抗原来源 | Rabbit |
| 保质期 | 1年 |
| 抗体英文名 | Anti-Glycogenin 1/FITC |
| 抗体名 | Anti-Glycogenin 1/FITC |
| 标记物 | FITC标记 |
| 宿主 | Human, Mouse, Rat, Dog, Cow, Sheep, |
| 适应物种 | Human, Mouse, Rat, Dog, Cow, Sheep, |
| 免疫原 | 详见说明书 |
| 亚型 | IGg |
| 形态 | 粉末、液体、冻干粉 |
| 应用范围 | ICC=1:50-200 IF=1:50-200 |
| 浓度 | 1mg/ml |
| 保存条件 | -20 °C |
| 规格 | 100ul |
| 英文名称 | Anti-Glycogenin 1/FITC |
| 中文名称 | FITC标记的糖原蛋白1 |
| 别 名 | Glycogenin; Glycogenin-1; Glycogenin1; GLYG_HUMAN; GN-1; GN1; GYG 1; GYG; GYG1. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 细胞生物 信号转导 糖蛋白 新陈代谢 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, Cow, Sheep, |
| 产品应用 | ICC=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 39kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Glycogenin 1 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Glycogen synthesis initiated by the autoglucosylation of Glycogenin-1. Specifically, Glycogenin-1 glucosylates itself to begin the synthesis of glycogen in mammalian skeletal muscle. It acts as the primer to which further glucose monomers may be added. All of the Glycogenin-1 molecules contain at least one glucosyl residue before autoglucosylation begins. The first step of the glycogen synthesis occurs when a glucose molecule from UDP-glucose binds to the hydroxyl group of Tyr 194 on the Glycogenin-1 molecule. Using its glucosyltransferase activity, Glycogenin-1 adds more glucoses, each one coming from UDP-glucose. The glycosylation process reaches a plateau when five new glucose residues have been added, at which point glycogen synthase (GS) takes over and further elongates the chain. Glycogenin-1 remains covalently attached to the reducing end of the glycogen molecule. Function: Self-glucosylates, via an inter-subunit mechanism, to form an oligosaccharide primer that serves as substrate for glycogen synthase. Subunit: Homodimer tightly complexed to the 86 kDa catalytic subunit of glycogen synthase GYS1. Post-translational modifications: Self-glycosylated by the transfer of glucose residues from UDP-glucose to itself, forming an alpha-1,4-glycan of around 10 residues attached to Tyr-195. Phosphorylated. DISEASE: Defects in GYG1 are the cause of glycogen storage disease type 15 (GSD15) [MIM:613507]. It is a metabolic disorder resulting in muscle weakness, associated with the glycogen depletion in skeletal muscle, and cardiac arrhythmia, associated with the accumulation of abnormal storage material in the heart. The skeletal muscle shows a marked predominance of slow-twitch, oxidative muscle fibers and mitochondrial proliferation. Similarity: Belongs to the glycogenin family. Database links: Entrez Gene: 2992 Human Omim: 603942 Human SwissProt: P46976 Human Unigene: 477892 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
